ANL Profile
Adlai Nortye Ltd. is a clinical-stage biotechnology firm dedicated to the discovery and development of cutting-edge cancer therapies in the United States and Mainland China.
The companys flagship product is AN2025, a potent pan-phosphoinositide 3-kinase (PI3K) inhibitor currently undergoing Phase III clinical trials. AN2025 is targeted at treating recurrent or metastatic head and neck squamous cell carcinomas, aiming to provide a new, effective treatment option for patients with these challenging cancers. Adlai Nortye's commitment to oncology extends through its diverse pipeline, which includes several innovative drug candidates.
Among its development programs, Adlai Nortye is advancing AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment. This agent aims to alter immune cell interactions within tumors, potentially enhancing the effectiveness of cancer treatments. Another key candidate is AN4005, an oral small-molecule PD-L1 inhibitor that targets PD-L1 dimerization to disrupt the PD-1/PD-L1 interaction, which is crucial in evading immune surveillance.
In addition to these clinical candidates, Adlai Nortye is progressing a number of preclinical assets. These include AN8025, a multifunctional antibody modulating T cells and antigen-presenting cells (APCs); AN1025, an oral small molecule degrader of ß-catenin, which plays a significant role in various cancers; and AN9025, an oral pan-KRAS inhibitor designed to target KRAS mutations prevalent in many cancer types. Founded in 2018 and headquartered in Grand Cayman, the Cayman Islands, Adlai Nortye continues to expand its research and development efforts, leveraging its global expertise to advance innovative cancer therapies.
|
